Form 4: Kezar Life Sciences Director Granted 5,000 Stock Options

Kezar Life Sciences, Inc. Director Franklin M. Berger was granted 5,000 stock options with an exercise price of $4.46, vesting fully in June 2026.

Summary

• Franklin M. Berger, a Director of Kezar Life Sciences, Inc. (KZR), was granted 5,000 stock options.
• The transaction date for this grant was June 18, 2025.
• The exercise price for these stock options is $4.46 per share.
• The options will vest 100% on June 18, 2026, contingent upon Mr. Berger's continued service to the company.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Berger beneficially owns 5,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is mildly positive as the grant of stock options to a director is a standard practice that aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors. However, it does not reflect direct operational or financial performance.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of Kezar Life Sciences, Inc.

Future Outlook

This document, an SEC Form 4, reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

The grant of stock options to a director is a common and standard practice across various industries for executive and board member compensation. It is designed to incentivize long-term commitment and align the interests of the director with those of the company's shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of compensation packages in publicly traded companies across industries.
• This document does not provide sufficient context to compare the specific size or terms of this grant against industry benchmarks for director compensation or against the performance of comparable companies or projects.

Related Party Transactions

• The grant of stock options to Franklin M. Berger, a Director of Kezar Life Sciences, Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options can align the director's interests with shareholder value creation, but also represents potential future dilution if the options are exercised.

Next Steps

• The stock options will vest on June 18, 2026, provided the reporting person continues to provide service.
• Following vesting, the reporting person will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date of June 17, 2035.

Key Dates

Keywords

Kezar Life Sciences, KZR, Stock Option, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant